Takeda to collaborate with JCR Pharma to commercialise next-gen Hunter Syndrome therapy
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age
Initially launched in Europe, this new service gives customers access to a range of digital health services and medical professionals and is part of its Digital Access to Care Initiative
In March it launched its first plastic-free toothbrush packaging, which included Sensodyne Pronamel and parodontax brushes in the US. Asia Pacific rollout of this commenced in Australia
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
The transaction is expected to close in the Q4FY22
TLD is recommended by WHO, USAID, and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg
Subscribe To Our Newsletter & Stay Updated